Compare CRSP & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | OUT |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Switzerland | United States |
| Employees | 393 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 2016 | 2013 |
| Metric | CRSP | OUT |
|---|---|---|
| Price | $51.20 | $33.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $70.29 | $28.50 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | $289,590,000.00 | ★ $1,831,700,000.00 |
| Revenue This Year | $807.72 | $6.19 |
| Revenue Next Year | $172.52 | $3.08 |
| P/E Ratio | ★ N/A | $302.14 |
| Revenue Growth | ★ 9169.85 | 0.04 |
| 52 Week Low | $44.12 | $16.64 |
| 52 Week High | $78.48 | $34.96 |
| Indicator | CRSP | OUT |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 58.53 |
| Support Level | $47.92 | $29.78 |
| Resistance Level | $59.61 | $33.94 |
| Average True Range (ATR) | 3.39 | 0.93 |
| MACD | -0.83 | 0.03 |
| Stochastic Oscillator | 12.78 | 68.73 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.